Q-omics provides the consensus-scored GPR176 profile across patient tissues and cancer cell-line models. GPR176 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GPR176 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, GPR176 RNA expression shows 19,000 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, HNSC, and THYM as cancer lineages where GPR176 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR176 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR176 survival associations across molecular data types. GPR176 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR176 RNA expression–survival associations across cancer types. High GPR176 expression shows unfavorable associations in UVM, STAD, MESO, KIRP and ACC, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GPR176 RNA expression.
This table summarizes GPR176 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GPR176. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR176 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, COAD, LIHC and STAD. The HNSC box plot shows higher GPR176 RNA expression in tumor versus normal tissue (log2 FC = +3.460, t-test p < 0.001).
This table shows molecular features associated with GPR176 in patient tissues and cancer cell lines. In patient samples, GPR176 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR176 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
